Fecal microbiota transplantation in the metabolic diseases: Current status and perspectives

Ji, Yong-Yi; Wen, Xin-Li; Duan, Sheng-Lei

doi:10.3748/wjg.v28.i23.2546

Cited by 23 publications

(22 citation statements)

References 138 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In CD, CEACAM6 is a receptor for AIEC in the intestinal mucosa, and increased CEACAM6 expression on the apical membrane of ileum cells promoted the abnormal colonization of AIEC in the ileum mucosa[ 9 ]. Furthermore, AIEC LF82 type I pili binding to CEACAM6 and TLR5 induced hiF-1A production and activated the classic NF-κB pathway, resulting in clinical colitis symptoms[ 10 ]. To mimic the high level of CEACAM6 expression in CD, transgenic CEABAC10-expressing mice were used to establish models expressing human CEACAMs.…”

Section: Introductionmentioning

confidence: 99%

Role of adherent invasive Escherichia coli in pathogenesis of inflammatory bowel disease

Duan¹,

Dai²,

Wu³

2022

World J Clin Cases

Self Cite

View full text Add to dashboard Cite

Gut microbiota imbalances play an important role in inflammatory bowel disease (IBD), but no single pathogenic microorganism critical to IBD that is specific to the IBD terminal ileum mucosa or can invade intestinal epithelial cells has been found. Invasive Escherichia coli ( E. coli) adhesion to macrophages is considered to be closely related to the pathogenesis of inflammatory bowel disease. Further study of the specific biological characteristics of adherent invasive E. coli (AIEC) may contribute to a further understanding of IBD pathogenesis. This review explores the relationship between AIEC and the intestinal immune system, discusses the prevalence and relevance of AIEC in Crohn's disease and ulcerative colitis patients, and describes the relationship between AIEC and the disease site, activity, and postoperative recurrence. Finally, we highlight potential therapeutic strategies to attenuate AIEC colonization in the intestinal mucosa, including the use of phage therapy, antibiotics, and anti-adhesion molecules. These strategies may open up new avenues for the prevention and treatment of IBD in the future.

show abstract

Section: Introductionmentioning

confidence: 99%

Role of adherent invasive Escherichia coli in pathogenesis of inflammatory bowel disease

Duan¹,

Dai²,

Wu³

2022

World J Clin Cases

Self Cite

View full text Add to dashboard Cite

show abstract

“…FMT is a process in which feces from healthy people are transferred to patients, and it was first used to treat patients with recurrent Clostridium difficile infection. Recent studies have shown that FMT can significantly improve the composition of BAs in the gut of patients with C. difficile , increase the content of secondary BAs and prevent C. difficile colonization[ 141 ]. Because of its apparent efficacy in treating recurrent C. difficile infection, it has been applied to other intestinal diseases, such as IBD, IBS, and pancreatitis.…”

Section: Intestinal Flora Ba Metabolism and Ibdmentioning

confidence: 99%

“…In IBD studies, FMT has shown significant efficacy in inducing remission of UC. A study of UC in children showed that the gut microbiota and metabolome of FMT responders were significantly more similar to those of healthy people[ 141 ].…”

Section: Intestinal Flora Ba Metabolism and Ibdmentioning

confidence: 99%

“…In a 12-wk clinical study, the nonabsorbable antibiotic rifaximin showed higher remission rates in patients with active CD. Given that different antibiotics have different effects on BA concentration and composition as well as IBD, antibiotic and patient selection will be important in evaluating antibiotic efficacy against IBD in the future[ 141 ].…”

Section: Intestinal Flora Ba Metabolism and Ibdmentioning

confidence: 99%

See 1 more Smart Citation

New insights into the interplay between intestinal flora and bile acids in inflammatory bowel disease

Zheng

2022

World J Clin Cases

Self Cite

View full text Add to dashboard Cite

Intestinal flora plays a key role in nutrient absorption, metabolism and immune defense, and is considered to be the cornerstone of maintaining the health of human hosts. Bile acids synthesized in the liver can not only promote the absorption of fat-soluble substances in the intestine, but also directly or indirectly affect the structure and function of intestinal flora. Under the action of intestinal flora, bile acids can be converted into secondary bile acids, which can be reabsorbed back to the liver through the enterohepatic circulation. The complex dialogue mechanism between intestinal flora and bile acids is involved in the development of intestinal inflammation such as inflammatory bowel disease (IBD). In this review, the effects of intestinal flora, bile acids and their interactions on IBD and the progress of treatment were reviewed.

show abstract

“…These perturbations to fecal microbiome composition can directly impact host health. Recent research shows that Fecal Microbiota Transplants (FMT), which involve the transfer of fecal microbes from a healthy donor into the gastrointestinal tract of a recipient animal, show promise in treating or preventing a range of health conditions and improving health outcomes [17][18][19]. FMTs can repopulate the microbiome and restore fecal microbiome composition, diversity, and homeostasis by increasing microbiome diversity, enhancing the numbers of beneficial microbes, or outcompeting pathogens [17][18][19].…”

Section: Introductionmentioning

confidence: 99%

Microbiome Responses to Fecal Microbiota Transplantation in Cats with Chronic Digestive Issues

Rojas¹,

Entrolezo²,

Jarett³

et al. 2023

Preprint

View full text Add to dashboard Cite

There is growing interest in the application of fecal microbiota transplants (FMTs) in small animal medicine, but there are few published studies that have tested their effectiveness in the domestic cat (Felis catus). Here we use 16S rRNA gene sequencing to examine fecal microbiome changes in 68 domestic cats with chronic digestive issues that underwent FMT treatment using lyophilized stool that was delivered in oral capsules. Fecal samples were collected from FMT recipients before and two weeks after treatment, as well as from their stool donors, and healthy animals. We found that according to their owners, 77% of cats were reported to show improvement in their clinical signs (termed ‘Responders’), and 23% were reported to exhibit no change or a worsening of their clinical signs (termed ‘Non-Responders’). Variation in the fecal microbiomes of FMT recipients most strongly correlated with host clinical signs, diet, and IBD diagnosis. The relative abundances of Collinsella, Negativibacillus, Parabacteroides, and Peptoclostridium changed differentially in FMT recipients. Overall, on average 13% of the bacterial amplicon sequence variants (ASVs) were shared between stool donors and FMT recipients (excluding ASVs already present in FMT recipients prior to treatment). The most commonly shared ASVs were classified as Prevotella 9, Peptoclostridium, Bacteroides, Collinsella and unclassified Lachnospiraceae. Lastly, FMT recipients that had recently taken antibiotics exhibited increases in microbiome similarity to an age-matched healthy reference set compared to other cats. Cats that had diarrhea or diarrhea with vomiting became more similar to healthy cats than did cats exhibiting other clinical signs. Overall, our results suggest that oral capsule FMT treatment was effective in this group of cats and microbiome responses may be modulated by the FMT recipient’s initial presenting clinical signs, prior IBD diagnosis, recent antibiotic use, and their diet.

show abstract

Fecal microbiota transplantation in the metabolic diseases: Current status and perspectives

Cited by 23 publications

References 138 publications

Role of adherent invasive Escherichia coli in pathogenesis of inflammatory bowel disease

Role of adherent invasive Escherichia coli in pathogenesis of inflammatory bowel disease

New insights into the interplay between intestinal flora and bile acids in inflammatory bowel disease

Microbiome Responses to Fecal Microbiota Transplantation in Cats with Chronic Digestive Issues

Contact Info

Product

Resources

About